Protalix to Develop More Plant-Cell Drugs, CEO Says

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

May 7 (Bloomberg) -- David Aviezer, president and chief executive officer of Protalix BioTherapeuticss Inc., talks about the company's first product to win approval from the U.S. Food and Drug Administration. The drug, Elelyso, was developed with Pfizer Inc. to treat the most common form of Gaucher disease. Aviezer speaks with Sara Eisen on Bloomberg Television's "InsideTrack." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change